JP2021522303A5 - - Google Patents

Info

Publication number
JP2021522303A5
JP2021522303A5 JP2020561788A JP2020561788A JP2021522303A5 JP 2021522303 A5 JP2021522303 A5 JP 2021522303A5 JP 2020561788 A JP2020561788 A JP 2020561788A JP 2020561788 A JP2020561788 A JP 2020561788A JP 2021522303 A5 JP2021522303 A5 JP 2021522303A5
Authority
JP
Japan
Prior art keywords
region
substitution
sequence shown
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561788A
Other languages
English (en)
Japanese (ja)
Other versions
JP7649139B2 (ja
JP2021522303A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/061455 external-priority patent/WO2019211472A1/en
Publication of JP2021522303A publication Critical patent/JP2021522303A/ja
Publication of JP2021522303A5 publication Critical patent/JP2021522303A5/ja
Priority to JP2025035978A priority Critical patent/JP2025085008A/ja
Application granted granted Critical
Publication of JP7649139B2 publication Critical patent/JP7649139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561788A 2018-05-03 2019-05-03 抗体バリアントの組み合わせおよびその使用 Active JP7649139B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025035978A JP2025085008A (ja) 2018-05-03 2025-03-07 抗体バリアントの組み合わせおよびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201800195 2018-05-03
DKPA201800195 2018-05-03
DKPA201800644 2018-09-26
DKPA201800644 2018-09-26
PCT/EP2019/061455 WO2019211472A1 (en) 2018-05-03 2019-05-03 Antibody variant combinations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025035978A Division JP2025085008A (ja) 2018-05-03 2025-03-07 抗体バリアントの組み合わせおよびその使用

Publications (3)

Publication Number Publication Date
JP2021522303A JP2021522303A (ja) 2021-08-30
JP2021522303A5 true JP2021522303A5 (enExample) 2022-05-13
JP7649139B2 JP7649139B2 (ja) 2025-03-19

Family

ID=66476613

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561788A Active JP7649139B2 (ja) 2018-05-03 2019-05-03 抗体バリアントの組み合わせおよびその使用
JP2025035978A Pending JP2025085008A (ja) 2018-05-03 2025-03-07 抗体バリアントの組み合わせおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025035978A Pending JP2025085008A (ja) 2018-05-03 2025-03-07 抗体バリアントの組み合わせおよびその使用

Country Status (13)

Country Link
US (1) US12338289B2 (enExample)
EP (1) EP3788074A1 (enExample)
JP (2) JP7649139B2 (enExample)
KR (1) KR20210008380A (enExample)
CN (1) CN112839958A (enExample)
AU (1) AU2019264217B2 (enExample)
BR (1) BR112020022179A2 (enExample)
CA (1) CA3098486A1 (enExample)
MA (1) MA52485A (enExample)
MX (1) MX2020011552A (enExample)
PH (1) PH12020551808A1 (enExample)
SG (1) SG11202010601VA (enExample)
WO (1) WO2019211472A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3580233A1 (en) 2017-02-10 2019-12-18 Genmab B.V. Polypeptide variants and uses thereof
MX2022007202A (es) * 2019-12-13 2022-10-07 Cugene Inc Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
UY39174A (es) * 2020-04-17 2021-10-29 Janssen Biotech Inc Poblaciones de glicoproteínas biosintéticas
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
MX2023010567A (es) * 2021-03-12 2023-09-21 Genmab As Variantes de anticuerpos no activadoras.
AU2022369298A1 (en) * 2021-10-20 2024-06-06 Janssen Biotech, Inc. Biosynthetic biparatopic or bispecific binding molecules with enhanced effector functions
EP4644413A1 (en) 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
ES2665422T3 (es) 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
CN101074261A (zh) 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2010145895A1 (en) 2009-05-14 2010-12-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
SG10201501803YA (en) 2010-03-12 2015-05-28 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
BR112012031727B1 (pt) 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
ES2758979T3 (es) 2012-07-06 2020-05-07 Genmab Bv Proteína dimérica con mutaciones triples
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
KR20200024345A (ko) * 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
CA2945882A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
KR20180002653A (ko) * 2015-04-07 2018-01-08 제넨테크, 인크. 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
CN109476737A (zh) 2015-12-01 2019-03-15 根马布有限公司 抗dr5抗体及其使用方法
CN108779182A (zh) * 2015-12-28 2018-11-09 麻省理工学院 具有恒定区突变的双特异性抗体及其用途
WO2018031258A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
EP3580233A1 (en) 2017-02-10 2019-12-18 Genmab B.V. Polypeptide variants and uses thereof
US20230399414A1 (en) 2017-03-31 2023-12-14 Genmab Holding B.V, Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
JP7330942B2 (ja) 2017-03-31 2023-08-22 ジェンマブ ホールディング ビー.ブイ. 二重特異性抗cd37抗体、モノクローナル抗cd37抗体、およびそれらの使用方法
EP3635005A1 (en) 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
JP2023500701A (ja) 2019-11-06 2023-01-10 ジェンマブ ビー.ブイ. 抗体変種の組み合わせおよびその使用

Similar Documents

Publication Publication Date Title
JP2021522303A5 (enExample)
CN110891650B (zh) 制导和导航控制蛋白及其制造和使用方法
US11202828B2 (en) Therapeutic SIRP-α antibodies
RU2423381C2 (ru) Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
CN113454119B (zh) 抗btla抗体
CN111484555B (zh) 新型双特异性cd3/cd20多肽复合物
EP4249066A2 (en) Antibodies to tigit
CN109862910A (zh) 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
JP2019503363A (ja) 急性リンパ芽球性白血病を治療するための二重特異性の抗cd20/抗cd3抗体
CN114456272A (zh) 靶向afp肽/mhc复合体的构建体及其用途
JP2021510736A5 (enExample)
JP2020516309A5 (enExample)
JP2022538718A (ja) 二重特異性抗体及びその調製方法、使用
KR20250024104A (ko) 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
AU2022278013A1 (en) Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
CN112292399A (zh) 抗cd27抗体及其用途
JP2021522303A (ja) 抗体バリアントの組み合わせおよびその使用
JP2024073580A (ja) Btla抗体
TWI889761B (zh) Cd137結合分子及其用途
JP2022517216A5 (enExample)
JP2023500701A5 (enExample)
JP2024534116A5 (enExample)
JP2021528439A5 (enExample)
CN113975385A (zh) 新型双特异性抗cd3/cd20多肽复合物配制剂
Gupta et al. Therapeutic human monoclonal antibodies